Selling, General, and Administrative Costs: Evotec SE vs Novavax, Inc.

A Tale of Two Companies: Evotec SE vs. Novavax, Inc.

In the ever-evolving landscape of biotechnology, understanding the financial dynamics of key players is crucial. Over the past decade, Evotec SE and Novavax, Inc. have demonstrated contrasting trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Evotec SE's SG&A expenses grew by approximately 840%, reflecting its strategic investments in research and development. Meanwhile, Novavax, Inc. experienced a staggering increase of over 2,250% in the same period, driven by its aggressive expansion and vaccine development efforts.

Key Insights

• 2014-2019: Both companies maintained a steady growth in expenses, with Novavax slightly ahead.
• 2020-2023: Novavax's expenses surged, peaking in 2022, as it ramped up operations during the global health crisis.

These trends highlight the distinct paths these companies have taken, offering valuable insights into their operational strategies and market positioning.